Perinatal Stem Cells

Research and Therapy
Erscheinungsjahr 2018
ISBN: 978-0-12-812015-6
Verlag: Elsevier Science

Buch, Englisch, 418 Seiten, Format (B × H): 288 mm x 227 mm, Gewicht: 1560 g

Perinatal Stem Cells provides researchers and clinicians with a comprehensive description of the current clinical and pre-clinical applications of stem cells derived from perinatal sources, such as amniotic fluid, placenta and placental membranes, the umbilical cord and Wharton’s jelly. It's compiled by leading experts in the field, offering readers detailed insights into sources of perinatal stem cells and their potential for disease treatment. Therapeutic applications of perinatal stem cells include the treatment of in utero and pregnancy related diseases, cardiac disease, liver disease, pulmonary disease, inflammatory diseases, for hematopoietic regeneration, and for neural protection after stroke or traumatic brain injury.

In addition, the rapid advance in clinical translation and commercialization of perinatal stem cell therapies is highlighted in a section on Clinical and Industry Perspective which provides insight into the new opportunities and challenges involved in this novel and exciting industry.

Autoren/Hrsg.

Atala, Anthony

Cetrulo, Kyle J.

Taghizadeh, Rouzbeh R.

Cetrulo, Curtis L

Murphy, Sean

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gynäkologie, Geburtshilfe
• Technische Wissenschaften Sonstige Technologien | Angewandte Technik Medizintechnik, Biomedizintechnik
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Medizintechnik, Biomedizintechnik, Medizinische Werkstoffe

Inhaltsverzeichnis

Section I. Amniotic Fluid-Derived Stem Cells

1. In utero therapy for congenital disorders using amniotic fluid stem cells

2. The Amniotic Fluid Stem Cell Secretome: at the Heart of Regeneration

3. Transplantation of Amniotic Fluid-Derived Neural Stem Cells

4. Stroke therapy: the potential of amniotic fluid-derived stem cells

5. Vascular formation by human perinatal stem cells

6. Amniotic Fluid Stem Cells for Kidney Regeneration

Section II. Placental and Placental Membrane-Derived Stem Cells

7. Placental mesenchymal stem cells for cellular cardiomyoplasty

8. Heterogeneous functions of perinatal mesenchymal stromal cells require a preselection before their banking for clinical use

9. Defining the fetal stem cell niche in the human placenta

10. Banking placental tissue hematopoietic stem cells and mesenchymal stem cells for clinical use

11. Immuno-modulatory mechanisms of placental stem cells

12. Amnion Membrane Allograft for Regenerative Medicine

13. Perinatal cells and biomaterials for wound healing

14. Placental Stem Cells

15. Therapeutic Effect of Extracellular Vesicles Derived from Adult/Perinatal Human Mesenchymal Stem Cells

Section III. Umbilical Cord-Derived Cells

16. Ex-vivo Expansion of Cord Blood Stem Cells

17. Cord Blood Transplantation: Therapeutic Use of Perinatal Stem Cells

18. Autologous Human Cord Blood as a Treatment for Traumatic Brain Injury in Children

19. Phenotypic and Functional Characterization Perinatal Stem Cells Isolated from Umbilical Cord Tissue

20. Mesenchymal stromal cells from Wharton’s jelly (WJ-MSCs): coupling their hidden differentiative program with their frank immunomodulatory phenotype

21. Regeneration of ischemic cardiovascular damage using Jelly Wharton as an unlimited source of therapeutic stem cells

22. Phenotype with Focused Paracrine Fractions: Effecting Future Phenotype with Focused Paracrine Fractions

Section IV. Clinical and Industry Perspective

23. Clinical Translation of Perinatal Stem Cell Therapy

24. Current Clinical Trials utilizing Perinatal Stem Cells – A Review

25. Review Of Processing Technology and Techniques for Perinatal Stem Cells Banking And Clinical Applications

26. Clinical Development And Commercialization Of Placenta-Derived Cell Therapy

27. How the patent landscape has changed

28. The Need for Better Assays to Predict the Effectiveness of Tissue Stem Cell Treatments

Über Autor(innen)

Atala, Anthony
Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine. Seventeen of his lab’s technologies have been translated to patients, including the first tissue-engineered organ for permanent implantation in a human. His research led to the discovery of a multipotent source of stem cells from amniotic fluid and placenta, advances in 3D printing of tissues and organs, and body-on-a-chip technologies. His work was twice listed among Time Magazine’s top 10 medical breakthroughs of the year, and he is a recipient of the Smithsonian Ingenuity Award. He has published over 900 journal articles, is the editor of 25 books, and holds over 250 national and international patents. Dr. Atala is a member of the National Academy of Medicine, the National Academy of Inventors, and the American Institute for Medical and Biological Engineering.